21+
Age Verification
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
GLP2-TZ is a first-in-class dual incretin agonist that simultaneously targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This 39-amino acid peptide represents a novel approach to multi-receptor engagement, distinguished by its unique dual-agonist mechanism that activates two distinct incretin pathways in a single molecular entity.
Engineered with a C20 fatty diacid moiety, tirzepatide exhibits extended pharmacokinetic profiles in preclinical models through enhanced albumin binding. The compound's dual receptor activity has been extensively characterized across multiple landmark Phase III clinical studies, establishing it as one of the most rigorously studied dual-agonist research peptides in the incretin class.
AXOM GLP2-TZ is manufactured under strict cGMP-equivalent protocols and verified to ≥99% purity via reverse-phase HPLC. Each lot is accompanied by a Certificate of Analysis documenting identity, purity, peptide content, and endotoxin levels. Available in 10mg and 20mg lyophilized formats.
Simultaneously engages both GIP and GLP-1 receptors — a first-in-class dual incretin mechanism for comprehensive in-vitro research applications.
Unique GIP receptor engagement alongside GLP-1 activity enables study of dual incretin pathway interactions not achievable with single-receptor agonists.
≥99% HPLC-verified purity with full COA documentation. Every lot independently tested by third-party analytical laboratories.
Landmark phase 3 study evaluating tirzepatide's dual GIP/GLP-1 receptor activity in a randomized, double-blind, placebo-controlled setting with 2,539 participants. Demonstrated the unique pharmacological profile of simultaneous dual incretin receptor engagement over 72 weeks, establishing foundational activity data for the dual-agonist class.
Head-to-head phase 3 comparative study characterizing tirzepatide's dual-agonist pharmacological profile against a single GLP-1 receptor agonist in 1,879 subjects. Provided critical data on the differential receptor engagement characteristics of dual versus single incretin pathway activation over 40 weeks.
Phase 3 monotherapy study evaluating tirzepatide's dual incretin receptor activity across multiple concentrations in 478 subjects. Established the dose-dependent pharmacological profile and confirmed consistent dual GIP/GLP-1 receptor engagement across the evaluated concentration range over 40 weeks.
| Product Name | GLP2-TZ (Tirzepatide) |
| Synonyms | LY3298176 |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | ~4,813.45 Da |
| Sequence Length | 39 amino acids |
| Receptor Targets | GIP and GLP-1 (dual agonist) |
| Modification | C20 fatty diacid at Lys-20 via linker (albumin-binding) |
| Purity | ≥99% (Reverse-Phase HPLC) |
| Form | Lyophilized white powder |
| Available Sizes | 10mg, 20mg |
| Solubility | Soluble in sterile water, bacteriostatic water |
| Endotoxin | <1 EU/μg (LAL method) |
| Certification | COA included with every order |
| Intended Use | For research and laboratory use only |
GLP2-TZ is supplied as a lyophilized powder and should be reconstituted with sterile bacteriostatic water (BAC water) for research applications.
All orders ship within the continental United States via USPS or UPS. Peptides are shipped at ambient temperature — lyophilized peptides are stable during transit. Free shipping on orders over $250.
